Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE

NCT05649046 is registered in ClinicalTrials.gov with Assistance Publique Hopitaux De Marseille as lead sponsor.

NCT NCT05649046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05649046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE
Lead sponsor
Assistance Publique Hopitaux De Marseille
Phase
Not applicable
Overall status
Unknown status
Start date
January 23, 2023
Completion date
June 1, 2024
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atheroma, chronic bronchitis, lung cancer, non-progressive cancer > 5 years, smoking-related pathology